Ifosfamide-induced encephalopathy and movement disorder

Pediatric Blood and Cancer

Volumn 54, Issue 4, 2010, Pages 624-626

  Ames, Bethany ^a   Lewis, Lionel D ^a   Chaffee, Sara ^a   Kim, Julie ^a   Morse, Richard ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Encephalopathy; Hemiballism; Ifosfamide; Movement disorder

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; DRONABINOL; IFOSFAMIDE; LORAZEPAM; MESNA; METHYLENE BLUE; ONDANSETRON; THIAMINE;

ADJUVANT THERAPY; ADOLESCENT; AGITATION; ALERTNESS; ANXIETY; ARTICLE; BRAIN DISEASE; CASE REPORT; CHILD; CONFUSION; DELIRIUM; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; FEMUR; HALLUCINATION; HAND TREMOR; HEMIBALLISM; HUMAN; IFOSFAMIDE INDUCED ENCEPHALOPATHY; INVOLUNTARY MOVEMENT; MALE; MOTOR DYSFUNCTION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OSTEOSARCOMA; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; TIC; URINE INCONTINENCE;

ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE NEOPLASMS; BRAIN DISEASES; CHILD; FEMALE; HUMANS; IFOSFAMIDE; MALE; MOVEMENT DISORDERS; NEUROTOXICITY SYNDROMES; OSTEOSARCOMA;

EID: 77649172171     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22361     Document Type: Article

References (17)

1. Ajithkumar T, Parkinson C, Shamshad F, et al. Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol) 2007;19:108-114.
2. Brunello A, Basso U, Rossi E, et al. Ifosfamide-related encephalopathy in elderly patients: Report of five cases and review of the literature. Drugs Aging 2007;24:967-973.
3. David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol 2005;28:277-280.
4. Park IS, Lee HJ, Lee YS, et al. Ifosfamide-induced encephalopathy with or without using methylene blue. Int J Gynecol Cancer 2005;15:807-810.
5. Rieger C, Fiegl M, Tischer J, et al. Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs 2004;15: 347-350.
6. Schiff D, Wen P. Central nervous system toxicity from cancer therapies. Hematol Oncol Clin North Am 2006;20:1377-1398.
7. Verstappen CC, Heimans JJ, Hoekman K, et al. Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs 2003;63:1549-1563.
8. Meyer T, Ludolph AC, Munch C. Ifosfamide encephalopathy presenting with asterixis. J Neurol Sci 2002;199:85-88.
9. Patel PN. Methylene blue for management of Ifosfamide-induced encephalopathy. Ann Pharmacother 2006;40:299-303.
10. Kerdudo C, Orbach D, Sarradet JL, et al. Ifosfamide neurotoxicity: An atypical presentation with psychiatric manifestations. Pediatr Blood Cancer 2006;47:100-102.
11. Pratt CB, Green AA, Horowitz ME, et al. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 1986;4:1253-1261.
12. Kupfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 1996;50:249-252.
13. Bruggers CS, Friedman HS, Tien R, et al. Cerebral atrophy in an infant following treatment with ifosfamide. Med Pediatr Oncol 1994;23:380-383.
14. Shuper A, Stein J, Goshen J, et al. Subacute central nervous system degeneration in a child: An unusual manifestation of ifosfamide intoxication. J Child Neurol 2000;15:481-483.
15. Buesa JM, Garcia-Teijido P, Losa R, et al. Treatment of ifosfamide encephalopathy with intravenous thiamin. Clin Cancer Res 2003;9: 4636-4637.
16. Hamadani M, Awan F. Role of thiamine in managing ifosfamide-induced encephalopathy. J Oncol Pharm Pract 2006;12:237-239.
17. Losa R, Sierra MI, Fernandez A, et al. Determination of thiamine and its phosphorylated forms in human plasma, erythrocytes and urine by HPLC and fluorescence detection: A preliminary study on cancer patients. J Pharm Biomed Anal 2005;37:1025-1029.